Mgr. Jitka Vaňáčková, Ph.D.
Assistant, Director's Office
Correspondence Address:
Kotlářská 267/2, 611 37 Brno
Office: bldg. C03/118
Kamenice 753/5
625 00 Brno
Phone: | +420 549 49 5681 |
---|---|
E‑mail: |
Total number of publications: 34
2017
-
A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein
Plos one, year: 2017, volume: 12, edition: 10, DOI
-
Preparation and Characterisation of Highly Stable Iron Oxide Nanoparticles for Magnetic Resonance Imaging
Journal of Nanomaterials, year: 2017, volume: 2017, edition: neuvedeno, DOI
-
Úvod do molekulární medicíny. Cvičení (biomarkerové studie)
Year: 2017, type:
2016
-
Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer
Oncotarget, year: 2016, volume: 7, edition: 1, DOI
-
Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy
ONCOTARGETS AND THERAPY, year: 2016, volume: 9, edition: July, DOI
2015
-
MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab
Oncotarget, year: 2015, volume: 6, edition: 36, DOI
-
MiR-215 is a tumor suppressor in colorectal cancer in vitro and in vivo
Year: 2015, type: Conference abstract
-
MiR-31-5p zvyšuje prediktivní hodnotu KRAS/NRAS/BRAF u pacientů s metastatickým kolorektálním karcinomem léčenýmch cetuximabem
Year: 2015, type: Conference abstract
-
Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.
BMC Cancer, year: 2015, volume: 15, edition: October, DOI
-
Sada pro predikci léčebné odpovědi na cetuximab
Year: 2015